Literature DB >> 9696421

DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.

T Seki1, M Minami, T Nakagawa, Y Ienaga, A Morisada, M Satoh.   

Abstract

Previously, we reported that replacement of the region from the fifth transmembrane domain to the C-terminus of kappa-opioid receptor with the corresponding region of mu-opioid receptor gives high affinity for [D-Ala2, N-MePhe4, Gly-ol5]enkephalin (DAMGO), a mu-opioid receptor-selective ligand, to the resultant chimeric receptor, suggesting that the difference in the amino acid sequence within this region is critical for the discrimination between mu- and kappa-opioid receptors by DAMGO. In the present study, we constructed further six mu/kappa-chimeric receptors and revealed that at least two separate regions around the third extracellular loop are critical for the discrimination between mu- and kappa-opioid receptors by DAMGO. Furthermore, we constructed several mutant receptors by a site-directed mutagenesis technique and found that the difference between Glu297 of kappa-opioid receptor and Lys303 of mu-opioid receptor in one region, and the difference between Ser310, Tyr312 and Tyr313 of kappa-opioid receptor and Val316, Trp318 and His319 of mu-opioid receptor in the other region, are critical for the discrimination between these receptors by DAMGO. The mutant receptor, kappa (E297K + Y313H + Y312W + S310V), in which the Glu297, Ser310, Tyr312 and Tyr313 of kappa-opioid receptor were changed to Lys, Val, Trp and His, respectively, bound to DAMGO with high affinity (Kd = 8.7 +/- 1.2 nM) and efficiently mediated the inhibitory effect of DAMGO on intracellular cAMP accumulation. The present results showed that these four amino acid residues act as determinants for the discrimination between mu- and kappa-opioid receptors by DAMGO.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696421     DOI: 10.1016/s0014-2999(98)00240-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

2.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

3.  The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.

Authors:  J Pil; J Tytgat
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).

Authors:  Kelly M DiMattio; Chongguang Chen; Lei Shi; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2014-12-04       Impact factor: 4.432

5.  A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.

Authors:  Chris M Brasel; Gregory W Sawyer; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2008-10-09       Impact factor: 4.432

6.  Functional expression and pharmacological modulation of TRPM3 in human sensory neurons.

Authors:  Laura Vangeel; Melissa Benoit; Yannick Miron; Paul E Miller; Katrien De Clercq; Patrick Chaltin; Catherine Verfaillie; Joris Vriens; Thomas Voets
Journal:  Br J Pharmacol       Date:  2020-03-05       Impact factor: 8.739

7.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

Review 8.  Peptide ligand recognition by G protein-coupled receptors.

Authors:  Brian E Krumm; Reinhard Grisshammer
Journal:  Front Pharmacol       Date:  2015-03-16       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.